

Sophisticated approaches to advanced RCC

Poster Session 69

Monday, 27 March
14:00 - 15:30

Location: Room Copenhagen, North Hall (Level 1)

Chairs: J.I. Martínez Salamanca, Majadahonda (ES)
V. Matveev, Moscow (RU)
M.C. Mir Maresma, Cleveland (US)

Aims and objectives of this session

To discuss different surgical aspects of nephrectomy for advanced RCC.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- 910 **Renal tumor management in Scandinavia: A multi-institutional survey**
By: Nisen H.¹, Jarvinen P.¹, Lund L.², Ljungberg B.³, Kromann-Andersen B.⁴, Gudmundsson E.⁵, Sundqvist P.⁶, Fovaeus M.⁷, Nilsen F.⁸, Beisland C.⁹
Institutes:¹HUCH Helsinki University Central Hospital, Dept. of Urology, Helsinki, Finland, ²Odense University Hospital, Dept. of Urology, Odense, Denmark, ³Umeå University, Dept. of Surgical and Perioperative Sciences, Umeå, Sweden, ⁴Herlev University Hospital, Dept. of Urology, Copenhagen, Denmark, ⁵Landspítali, Dept. of Urology, Reykjavik, Iceland, ⁶Örebro University Hospital, Dept. of Urology, Örebro, Sweden, ⁷Sahlgrenska University Hospital, Dept. of Urology, Gothenburg, Sweden, ⁸Akershus University Hospital, Dept. of Urology, Oslo, Norway, ⁹Haukelan University Hospital, Dept. of Urology, Bergen, Norway
- 911 **Multicenter analysis of oncologic and renal functional outcomes of radical and partial nephrectomy in stage II renal cell carcinoma**
By: Hamilton Z.¹, Correa A.², Larcher A.⁴, Khene Z.³, Fero K.¹, Han D.¹, Bloch A.¹, Field C.¹, Peyronnet B.³, Capitanio U.⁴, Montorsi F.⁴, Bensalah K.³, Uzzo R.², Derweesh I.¹
Institutes:¹Moore's Cancer Center, Dept. of Urology, La Jolla, United States of America, ²Fox Chase Cancer Center, Dept. of Urology, Philadelphia, United States of America, ³University of Rennes, Dept. of Urology, Rennes, France, ⁴San Raffaele Scientific Institute, Dept. of Urology, Milan, Italy
- 912 **Partial versus radical nephrectomy in patients with renal cell carcinoma and renal or caval thrombus: Oncological and functional outcomes from an individual matched cohort analysis**
By: Marra G.¹, Gontero P.¹, Brattoli M.¹, Filippini C.², Linares Espinos E.³, Capitanio U.⁴, Montorsi F.⁴, Daneshmand S.⁶, Huang W.C.⁷, Martínez-Salamanca J.I.⁸, McKiernan J.M.⁹, Scherr D.S.¹⁰, Zigeuner R.¹¹, Libertino J.A.⁵
Institutes:¹San Giovanni Battista Hospital, Dept. of Urology, Turin, Italy, ²San Giovanni Battista Hospital, Dept. of Urology, Turin, Italy, ³Hospital Universitario Puerta De Hierro-Madrid, Dept. of Urology, Madrid, Spain, ⁴San Raffaele Hospital, Dept. of Urology, Milan, Italy, ⁵Lahey Clinic, Dept. of Urology, Burlington, United States of America, ⁶USC/Norris Comprehensive Cancer Center, Dept. of Urology, Los Angeles, United States of America, ⁷University School of Medicine, Dept. of Urology, New York, United States of America, ⁸Hospital Universitario Puerta de Hierro-Majadahonda, Universidad Autónoma de Madrid, Dept. of Urology, Madrid, Spain, ⁹Columbia University College of Physicians and Surgeons, Dept. of Urology, New York, United States of America, ¹⁰Weill Cornell Medical Center, Dept. of Urology, New York, United States of America, ¹¹Medical University of Graz, Dept. of Urology, Graz, Austria
- 913 **Comparison of different surgical approaches for the management of renal cell carcinoma invading the renal vein**
By: Hanna N., Ingham M., Seisen T., Chang S.
Institutes:Brigham and Women's Hospital, Dept. of Urology, Boston, United States of America

- 914 **Robot assisted radical nephrectomy and inferior vena cava thrombectomy: Surgical technique, perioperative and oncologic outcomes**
By: Simone G.¹, Hatcher D.², Ferriero M.¹, Minisola F.¹, Misuraca L.¹, Tuderti G.¹, Guaglianone S.¹, De Castro Abreu A.L.², Aron M.², Desai M.², Gill I.S.², Gallucci M.¹
Institutes:¹Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, ²Keck School of Medicine, University of Southern California, Institute of Urology, Los Angeles, United States of America
- 915 **Robotic versus open inferior Vena cava (IVC) tumor thrombectomy: The initial comparison**
By: Chopra S., Loh-Doyle J., Cai J., Daneshman S., Djaladat H., Desai M., Gallucci M., Gill I.S.
Institutes:Usc Institute of Urology, Dept. of Urology, Los Angeles, United States of America
- 916 **Comparison between laparoendoscopic single site nephrectomy and conventional laparoscopic nephrectomy: A randomized control single institution experience**
By: Eltemamy M., Abdel Hakim M., El-Feel A., Abdel Wahab M., Abdallah A., Elshafei A., Omar A.-R.
Institutes:Cairo University, Dept. of Urology, Cairo, Egypt
- 917 **Impact of intraoperative blood transfusions on survival after surgery for renal cell carcinoma**
By: La Croce G., Muttin F., Moschini M., Larcher A., Dell'Oglio P., Nini A., Ripa F., Cianflone F., Di Trapani E., Carenci C., Dehò F., Montorsi F., Bertini R., Capitano U.
Institutes:IRCCS Ospedale San Raffaele, Urological Research Institute, Unit of Urology, Division of Oncology, Milan, Italy
- 918 **The efficacy of neoadjuvant targeted therapy in treatment of localized RCC**
By: Voylenko O., Vitruk I., Stakhovskiy O., Kononenko O., Pikul M., Stakhovsky E.
Institutes:National Cancer Institute, Dept. of Plastic and Reconstructive Oncological Urology, Kiev, Ukraine
- 919 **Clinical benefit of presurgical axitinib therapy in renal cell carcinoma patients with thrombus extending to inferior vena cava**
By: Tanaka Y., Hashimoto Y., Hatakeyama S., Hosogoe S., Noro D., Oikawa M., Tanaka T., Narita T., Hagiwara K., Tobisawa Y., Yamamoto H., Yoneyama T., Yoneyama T., Koie T., Ohyama C.
Institutes:Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan
- 920 **Phase II study of axitinib for downstaging cT2a to cT1 renal tumors for allowing partial nephrectomy (AXIPAN)**
By: Lebacle C.¹, Bernhard J.C.², Bensalah K.³, Baumert H.⁴, Lang H.⁵, Jacqmin D.⁵, Duclos B.⁶, Ravaud A.⁷, Laguerre B.⁸, Albiges L.⁹, Arnoux A.¹⁰, Escudier B.⁹, Patard J.J.¹
Institutes:¹Bicêtre University Hospital, Dept. of Urology, Le Kremlin-Bicêtre, France, ²Pellegrin Hospital, Dept. of Urology, Bordeaux, France, ³Pontchaillou University Hospital, Dept. of Urology, Rennes, France, ⁴Saint-Joseph Hospital, Dept. of Urology, Paris, France, ⁵Hôpitaux Universitaires De Strasbourg, Nouvel Hôpital Civil, Dept. of Urology, Strasbourg, France, ⁶Hôpitaux Universitaires De Strasbourg, Hôpital Hautepierre, Dept. of Oncology, Strasbourg, France, ⁷Saint-André Hospital, University Hospital, CHU Bordeaux, Dept. of Medical Oncology, Bordeaux, France, ⁸Eugène Marquis Center, Dept. of Oncology, Rennes, France, ⁹Gustave Roussy Université Paris-Saclay, Dept. of Medicine, Villejuif, France, ¹⁰Bicetre University Hospital, Dept. of Statistics, Le Kremlin-Bicêtre, France
- 921 **Meta-analysis of upfront VEGF targeted therapy prior to nephrectomy in metastatic clear cell renal cancer**
By: Szabados B.¹, Gomez De Liano Lista A.¹, Wimalasingham A.¹, De Bruijn R.², Haanen J.³, Blank C.³, Hall P.⁴, Staehler M.⁶, Chowdhury S.⁵, Hopkins T.⁴, Powles T.⁴, Bex A.²
Institutes:¹Barts Health Nhs Trust St Bartholomew's Hospital, Dept. of Oncology, London, United Kingdom, ²The Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, ³The Netherlands Cancer Institute, Dept. of Oncology, Amsterdam, The Netherlands, ⁴Barts Health NHS Trust St Bartholomew's Hospital, Dept. of Oncology, London, United Kingdom, ⁵Guy's, King's and St Thomas' Hospitals, Dept. of Oncology, London, United Kingdom, ⁶University Hospital Munich-

Grosshadern, Dept. of Urology, Munich, Germany

922

S-TRAC adjuvant sunitinib phase 3 trial in patients with high risk renal cell carcinoma: Subgroups analyses by risk factors

By: Stahler M.¹, Patard J.-J.², Pantuck A.³, Ravaud A.⁴, Motzer R.⁵, Pandha H.⁶, George D.⁷, Chang Y.-H.⁸, Escudier B.⁹, Donskov F.¹⁰, Magheli A.¹¹, Carteni G.¹², Laguerre B.¹³, Tomczak P.¹⁴, Breza J.¹⁵, Gerletti P.¹⁶, Lechuga M.¹⁶, Lin X.¹⁷, Casey M.¹⁸, Patel A.¹⁹

Institutes:¹University Hospital of Munich, Dept. of Urology, Munich, Germany, ²Bicêtre Hospital, Paris-Saclay University, Dept. of Urology, Le Kremlin Bicêtre, France, ³Ronald Reagan UCLA Medical Center, Dept. of Urology, Los Angeles, Ca, United States of America, ⁴Bordeaux University Hospital, Dept. of Medical Oncology, Bordeaux, France, ⁵Memorial Sloan Kettering Cancer Center, Dept. of Oncology, New York, United States of America, ⁶University of Surrey, Dept. of Clinical and Experimental Medicine, Surrey, United Kingdom, ⁷Duke Cancer Center, Dept. of Oncology, Durham, United States of America, ⁸Taipei Veterans General Hospital, Dept. of Urology, Taipei, Taiwan, ⁹Institut Gustave Roussy, Dept. of Medical Oncology, Villejuif, France, ¹⁰Aarhus University Hospital, Dept. of Oncology, Aarhus, Denmark, ¹¹Charité Universitätsmedizin Berlin, Dept. of Urology, Berlin, Germany, ¹²Azienda Ospedaliera Di Rilievo Nazionale A. Cardarelli, Dept. of Oncology and Urology, Naples, Italy, ¹³Centre Eugene Marquis, Dept. of Medical Oncology, Rennes, France, ¹⁴Klinika Onkologii Oddzial Chemioterapii, Dept. of Oncology, Poznan, Poland, ¹⁵Slovak Medical University In Bratislava, Dept. of Urology, Bratislava, Slovakia, ¹⁶Pfizer S.r.L, Dept. of Oncology, Milan, Italy, ¹⁷Pfizer Inc, Dept. of Oncology, La Jolla, United States of America, ¹⁸Pfizer Inc, Dept. of Oncology, New York, United States of America, ¹⁹Spire Roding Hospital, Dept. of Urology, London, United Kingdom

15:15 - 15:22

Summary

M.C. Mir Maresma, Cleveland (US)